RE: Angle19 Jul 2022 18:29
ah, a polite question - how refreshing! Well, ElderlyBird, I'm as annoyed as the next shareholder with the manner of the raise (and have said so the board) though I accept its good to have cash in the bank just now. It is a pivotal moment for Angle - there is undoubtedly huge interest in Parsortix post-FDA, and so we have to balance the likely slow uptake of testing (due to natural resistance) against the huge future value of the instrument across all cancer types. This future value is in plain sight of vulture companies. AN is shoring up the finances to resist a hostile bid, but in doing so he's made it even more attractive to the likes of Abbott. I've put almost all of my profit back in over the last two days, but I do intend to sell some just under £1, as I believe many who participated in the raise will do so too. Ovarian results should be along soon, so that will provide another moment of reflection...